RU2009101911A - Производные пиридина и пиразина в качестве ингибиторов mnk-киназы - Google Patents
Производные пиридина и пиразина в качестве ингибиторов mnk-киназы Download PDFInfo
- Publication number
- RU2009101911A RU2009101911A RU2009101911/04A RU2009101911A RU2009101911A RU 2009101911 A RU2009101911 A RU 2009101911A RU 2009101911/04 A RU2009101911/04 A RU 2009101911/04A RU 2009101911 A RU2009101911 A RU 2009101911A RU 2009101911 A RU2009101911 A RU 2009101911A
- Authority
- RU
- Russia
- Prior art keywords
- pyrazin
- alkyl
- indol
- amino
- amine
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 24
- -1 aminocarbonylphenyl Chemical group 0.000 claims abstract 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- 239000000651 prodrug Substances 0.000 claims abstract 12
- 229940002612 prodrug Drugs 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 125000001424 substituent group Chemical group 0.000 claims abstract 12
- 150000001204 N-oxides Chemical class 0.000 claims abstract 11
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims abstract 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 8
- 125000005843 halogen group Chemical group 0.000 claims abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 150000004677 hydrates Chemical class 0.000 claims abstract 5
- 230000003287 optical effect Effects 0.000 claims abstract 5
- 125000002252 acyl group Chemical group 0.000 claims abstract 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims abstract 4
- 125000001041 indolyl group Chemical group 0.000 claims abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims abstract 3
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims abstract 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims abstract 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 76
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims 3
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 3
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims 3
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- PNZKKQWBSPXAPD-UHFFFAOYSA-N 4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 PNZKKQWBSPXAPD-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- LHFZSYIZPPCJQA-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCC(N(C)C)C1 LHFZSYIZPPCJQA-UHFFFAOYSA-N 0.000 claims 2
- VEFWZQFPBUSMBL-UHFFFAOYSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCOCC1 VEFWZQFPBUSMBL-UHFFFAOYSA-N 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- IPBNVTMTIKJPSK-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CC(N)C1 IPBNVTMTIKJPSK-UHFFFAOYSA-N 0.000 claims 1
- NCJJBSPRMXVTIW-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 NCJJBSPRMXVTIW-UHFFFAOYSA-N 0.000 claims 1
- JNQRUUBGEMDSNI-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[6-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 JNQRUUBGEMDSNI-UHFFFAOYSA-N 0.000 claims 1
- XITUAKFNJMJXQZ-UHFFFAOYSA-N (4-methyl-1,4-diazepan-1-yl)-[6-[[6-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=NC=C3C=2)=N1 XITUAKFNJMJXQZ-UHFFFAOYSA-N 0.000 claims 1
- SCCCDOPYCXBGPY-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[[6-(1h-pyrrolo[2,3-c]pyridin-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CN=CC=C3C=2)=N1 SCCCDOPYCXBGPY-UHFFFAOYSA-N 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- XCUZPVBDBASDCD-UHFFFAOYSA-N 2,9-diazaspiro[4.5]decan-2-yl-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C1)CCC21CCCNC2 XCUZPVBDBASDCD-UHFFFAOYSA-N 0.000 claims 1
- PHLZSOMVNDLFQN-UHFFFAOYSA-N 2-[2-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-5-(4-methylpiperazine-1-carbonyl)phenoxy]-n,n-dimethylacetamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCC(=O)N(C)C)=CC=1C(=O)N1CCN(C)CC1 PHLZSOMVNDLFQN-UHFFFAOYSA-N 0.000 claims 1
- GMDXKZWRGGYIIL-UHFFFAOYSA-N 2-[6-[4-(4-methylpiperazine-1-carbonyl)anilino]pyrazin-2-yl]-1h-indole-5-carboxamide Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=C(C=C3C=2)C(N)=O)=N1 GMDXKZWRGGYIIL-UHFFFAOYSA-N 0.000 claims 1
- DPHUNMBXCBPBOC-UHFFFAOYSA-N 3-[[6-(1-benzofuran-2-yl)pyrazin-2-yl]amino]-4-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C1=C(NC=2N=C(C=NC=2)C=2OC3=CC=CC=C3C=2)C(OC)=CC=C1C(=O)N(C)C1CCN(C)C1 DPHUNMBXCBPBOC-UHFFFAOYSA-N 0.000 claims 1
- ZHRBUSCAJPHBJY-UHFFFAOYSA-N 3-chloro-n-[2-(diethylamino)ethyl]-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound ClC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 ZHRBUSCAJPHBJY-UHFFFAOYSA-N 0.000 claims 1
- ANESEZVJTLJYQN-UHFFFAOYSA-N 3-fluoro-4-[6-(6-fluoro-1h-indol-2-yl)pyrazin-2-yl]-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)C(F)=CC=1C(=O)N(C)C1CCN(C)C1 ANESEZVJTLJYQN-UHFFFAOYSA-N 0.000 claims 1
- PKUBWSRLUOHNPZ-UHFFFAOYSA-N 3-fluoro-5-[6-(6-fluoro-1h-indol-2-yl)pyrazin-2-yl]-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C(F)=CC(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)=CC=1C(=O)N(C)C1CCN(C)C1 PKUBWSRLUOHNPZ-UHFFFAOYSA-N 0.000 claims 1
- RZLKZEGKUUMPDQ-UHFFFAOYSA-N 3-methoxy-4-[[6-(4-methoxy-1h-indol-2-yl)pyrazin-2-yl]amino]-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(OC)=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 RZLKZEGKUUMPDQ-UHFFFAOYSA-N 0.000 claims 1
- OVSTYTDVQDWUBE-UHFFFAOYSA-N 3-methoxy-4-[[6-(5-methoxy-1h-indol-2-yl)pyrazin-2-yl]amino]-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C2=CC(OC)=CC=C2NC=1C(N=1)=CN=CC=1NC(C(=C1)OC)=CC=C1C(=O)N(C)C1CCN(C)C1 OVSTYTDVQDWUBE-UHFFFAOYSA-N 0.000 claims 1
- UNUXUUBNCRXUMH-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[6-(5-methyl-1h-indol-2-yl)pyrazin-2-yl]amino]-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(C)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 UNUXUUBNCRXUMH-UHFFFAOYSA-N 0.000 claims 1
- XMTXOOYCGUDHQX-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[6-(6-methyl-1h-indol-2-yl)pyrazin-2-yl]amino]-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(C)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 XMTXOOYCGUDHQX-UHFFFAOYSA-N 0.000 claims 1
- OGSUUHVBRCGZAU-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-n-(2,3-dihydroxypropyl)benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NCC(O)CO)C=C1 OGSUUHVBRCGZAU-UHFFFAOYSA-N 0.000 claims 1
- OGSUUHVBRCGZAU-INIZCTEOSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-n-[(2s)-2,3-dihydroxypropyl]benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NC[C@H](O)CO)C=C1 OGSUUHVBRCGZAU-INIZCTEOSA-N 0.000 claims 1
- HJANIWAXHMBUSG-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-n-[3-[bis(2-hydroxyethyl)amino]propyl]benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NCCCN(CCO)CCO)C=C1 HJANIWAXHMBUSG-UHFFFAOYSA-N 0.000 claims 1
- LANXWFYAJDTUQO-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-n-ethyl-n-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)N(CCO)CC)=CC=C1C1=CN=C(N)C(C=2OC3=CC=CC=C3C=2)=N1 LANXWFYAJDTUQO-UHFFFAOYSA-N 0.000 claims 1
- FANHFMGLTLDNKK-UHFFFAOYSA-N 4-[[6-(1-benzofuran-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2OC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 FANHFMGLTLDNKK-UHFFFAOYSA-N 0.000 claims 1
- YDYGKLHXQAFPOD-QGZVFWFLSA-N 4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-[(3r)-pyrrolidin-3-yl]benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N[C@@H]1CCNC1 YDYGKLHXQAFPOD-QGZVFWFLSA-N 0.000 claims 1
- YDYGKLHXQAFPOD-KRWDZBQOSA-N 4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-[(3s)-pyrrolidin-3-yl]benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N[C@H]1CCNC1 YDYGKLHXQAFPOD-KRWDZBQOSA-N 0.000 claims 1
- ZRZOSUIBWQOEGM-UHFFFAOYSA-N 4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-piperidin-3-ylbenzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)NC1CCCNC1 ZRZOSUIBWQOEGM-UHFFFAOYSA-N 0.000 claims 1
- JEUURUVLROAREY-UHFFFAOYSA-N 4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 JEUURUVLROAREY-UHFFFAOYSA-N 0.000 claims 1
- CGPRHVRLWRCWJA-UHFFFAOYSA-N 4-[[6-(4-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(F)=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 CGPRHVRLWRCWJA-UHFFFAOYSA-N 0.000 claims 1
- ZJPPAUXADIFCJC-UHFFFAOYSA-N 4-[[6-(5-chloro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(Cl)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 ZJPPAUXADIFCJC-UHFFFAOYSA-N 0.000 claims 1
- NWLPGLSOMDEYCD-UHFFFAOYSA-N 4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 NWLPGLSOMDEYCD-UHFFFAOYSA-N 0.000 claims 1
- GBTXJILKTQBTQO-UHFFFAOYSA-N 4-[[6-(6-chloro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(Cl)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 GBTXJILKTQBTQO-UHFFFAOYSA-N 0.000 claims 1
- KFNNXOYZKPSREJ-UHFFFAOYSA-N 4-[[6-(6-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 KFNNXOYZKPSREJ-UHFFFAOYSA-N 0.000 claims 1
- QDBWBNDBUKEGSC-UHFFFAOYSA-N 4-[[6-(7-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methyl-n-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=C(F)C=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 QDBWBNDBUKEGSC-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- RCOTZFFXLPZDMS-GOSISDBHSA-N [(3r)-3-(dimethylamino)pyrrolidin-1-yl]-[3-methoxy-4-[[6-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=NC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N(C)C)C1 RCOTZFFXLPZDMS-GOSISDBHSA-N 0.000 claims 1
- VMGFCBXBANWBPC-LJQANCHMSA-N [(3r)-3-(dimethylamino)pyrrolidin-1-yl]-[3-methoxy-4-[[6-(6-methoxy-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound N1C2=CC(OC)=CC=C2C=C1C(N=1)=CN=CC=1NC(C(=C1)OC)=CC=C1C(=O)N1CC[C@@H](N(C)C)C1 VMGFCBXBANWBPC-LJQANCHMSA-N 0.000 claims 1
- AHAWPPZIBXCDSQ-HXUWFJFHSA-N [(3r)-3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1[C@H](N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 AHAWPPZIBXCDSQ-HXUWFJFHSA-N 0.000 claims 1
- YSJOQWCLLYPLTQ-QGZVFWFLSA-N [(3r)-3-aminopyrrolidin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N)C1 YSJOQWCLLYPLTQ-QGZVFWFLSA-N 0.000 claims 1
- ONYIMVNCXQKHJT-QGZVFWFLSA-N [(3r)-3-aminopyrrolidin-1-yl]-[4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N)C1 ONYIMVNCXQKHJT-QGZVFWFLSA-N 0.000 claims 1
- XLWQOGPOLMFUFI-CALCHBBNSA-N [(3r,5s)-3,5-dimethylpiperazin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1C[C@H](C)N[C@H](C)C1 XLWQOGPOLMFUFI-CALCHBBNSA-N 0.000 claims 1
- IYIMGJPMKSLGNJ-IBGZPJMESA-N [(3s)-3-(dimethylamino)pyrrolidin-1-yl]-[3-methoxy-4-[[6-(5-nitro-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(C=C3C=2)[N+]([O-])=O)C(OC)=CC=1C(=O)N1CC[C@H](N(C)C)C1 IYIMGJPMKSLGNJ-IBGZPJMESA-N 0.000 claims 1
- AHAWPPZIBXCDSQ-FQEVSTJZSA-N [(3s)-3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1[C@@H](N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 AHAWPPZIBXCDSQ-FQEVSTJZSA-N 0.000 claims 1
- YSJOQWCLLYPLTQ-KRWDZBQOSA-N [(3s)-3-aminopyrrolidin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@H](N)C1 YSJOQWCLLYPLTQ-KRWDZBQOSA-N 0.000 claims 1
- MEQAZNGFRKGLQN-UHFFFAOYSA-N [2-chloro-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound ClC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)=CC=C1C(=O)N1CCNCC1 MEQAZNGFRKGLQN-UHFFFAOYSA-N 0.000 claims 1
- UOUOLDXTLRBHQM-UHFFFAOYSA-N [3-(2-ethoxyethoxy)-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCCOCC)=CC=1C(=O)N1CCN(C)CC1 UOUOLDXTLRBHQM-UHFFFAOYSA-N 0.000 claims 1
- YVCKXRKFCLDWNJ-UHFFFAOYSA-N [3-[2-(dimethylamino)ethoxy]-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCCN(C)C)=CC=1C(=O)N1CCN(C)CC1 YVCKXRKFCLDWNJ-UHFFFAOYSA-N 0.000 claims 1
- HMNYERMXRVUXNO-UHFFFAOYSA-N [3-chloro-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-[4-[3-(dimethylamino)propyl]piperazin-1-yl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C(C=C1Cl)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 HMNYERMXRVUXNO-UHFFFAOYSA-N 0.000 claims 1
- ARBYDFNSZUAGKQ-UHFFFAOYSA-N [3-chloro-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(Cl)=CC=1C(=O)N1CCNCC1 ARBYDFNSZUAGKQ-UHFFFAOYSA-N 0.000 claims 1
- TXTKMDKRXMPYGQ-UHFFFAOYSA-N [3-chloro-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1NC(C(=C1)Cl)=CC=C1C(=O)N1CCNCC1 TXTKMDKRXMPYGQ-UHFFFAOYSA-N 0.000 claims 1
- OYWGCGGTQRVVRG-UHFFFAOYSA-N [3-fluoro-4-[6-(1h-indol-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=C1 OYWGCGGTQRVVRG-UHFFFAOYSA-N 0.000 claims 1
- APJISWFEQVISDA-UHFFFAOYSA-N [3-fluoro-4-[6-(1h-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=CC=1C(=O)N1CCOCC1 APJISWFEQVISDA-UHFFFAOYSA-N 0.000 claims 1
- KUIRMWHHKSNSTJ-UHFFFAOYSA-N [3-methoxy-4-[[6-(6-methoxy-1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound N1C2=CC(OC)=CC=C2C=C1C(N=1)=CN=CC=1NC(C(=C1)OC)=CC=C1C(=O)N1CCNCC1 KUIRMWHHKSNSTJ-UHFFFAOYSA-N 0.000 claims 1
- NQSJRTIBZZCLEA-UHFFFAOYSA-N [4-[2-(dimethylamino)ethyl]piperazin-1-yl]-[3-fluoro-5-[6-(6-fluoro-1h-indol-2-yl)pyrazin-2-yl]phenyl]methanone Chemical compound C1CN(CCN(C)C)CCN1C(=O)C1=CC(F)=CC(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)=C1 NQSJRTIBZZCLEA-UHFFFAOYSA-N 0.000 claims 1
- AMJCKPNZDXRZSB-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[6-(1h-indol-2-yl)pyrazin-2-yl]phenyl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=C1 AMJCKPNZDXRZSB-UHFFFAOYSA-N 0.000 claims 1
- LJCCJXHEPSIOPN-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-2-methoxyphenyl]methanone Chemical compound COC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)=CC=C1C(=O)N1CCN(CCCN(C)C)CC1 LJCCJXHEPSIOPN-UHFFFAOYSA-N 0.000 claims 1
- STJFCFRPIAZTDO-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methylphenyl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C(C=C1C)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 STJFCFRPIAZTDO-UHFFFAOYSA-N 0.000 claims 1
- UGMCYWQTAFZSFE-UHFFFAOYSA-N [4-[5-(1h-indol-2-yl)pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=C1 UGMCYWQTAFZSFE-UHFFFAOYSA-N 0.000 claims 1
- ZIVCXJIWLIRETL-UHFFFAOYSA-N [4-[5-(1h-indol-2-yl)pyridin-3-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2C=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 ZIVCXJIWLIRETL-UHFFFAOYSA-N 0.000 claims 1
- DIGCBNOQNHBISN-UHFFFAOYSA-N [4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-3-fluorophenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2OC3=CC=CC=C3C=2)C(F)=C1 DIGCBNOQNHBISN-UHFFFAOYSA-N 0.000 claims 1
- NVMAZONXRCZIFD-UHFFFAOYSA-N [4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2OC3=CC=CC=C3C=2)C=C1 NVMAZONXRCZIFD-UHFFFAOYSA-N 0.000 claims 1
- FTZXELIUUGJIFS-UHFFFAOYSA-N [4-[5-amino-6-(1h-indol-2-yl)pyrazin-2-yl]-3-fluorophenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=C1 FTZXELIUUGJIFS-UHFFFAOYSA-N 0.000 claims 1
- NCJYQDIKWRZMGN-UHFFFAOYSA-N [4-[5-amino-6-(1h-indol-2-yl)pyrazin-2-yl]-3-fluorophenyl]-morpholin-4-ylmethanone Chemical compound N1=C(C=2NC3=CC=CC=C3C=2)C(N)=NC=C1C(C(=C1)F)=CC=C1C(=O)N1CCOCC1 NCJYQDIKWRZMGN-UHFFFAOYSA-N 0.000 claims 1
- PMUZRYBSGZBWRL-UHFFFAOYSA-N [4-[5-amino-6-(1h-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound N1=C(C=2NC3=CC=CC=C3C=2)C(N)=NC=C1C(C=C1)=CC=C1C(=O)N1CCOCC1 PMUZRYBSGZBWRL-UHFFFAOYSA-N 0.000 claims 1
- CUSBASMLBLPZHG-UHFFFAOYSA-N [4-[6-(1h-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 CUSBASMLBLPZHG-UHFFFAOYSA-N 0.000 claims 1
- IBEJZHNMZAVULE-UHFFFAOYSA-N [4-[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C=C1 IBEJZHNMZAVULE-UHFFFAOYSA-N 0.000 claims 1
- DGUSNOWIXMESGU-UHFFFAOYSA-N [4-[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1C(C=C1)=CC=C1C(=O)N1CCOCC1 DGUSNOWIXMESGU-UHFFFAOYSA-N 0.000 claims 1
- YCHVWRYIYRLCEF-UHFFFAOYSA-N [4-[6-(6-methyl-1h-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound N1C2=CC(C)=CC=C2C=C1C(N=1)=CN=CC=1C(C=C1)=CC=C1C(=O)N1CCOCC1 YCHVWRYIYRLCEF-UHFFFAOYSA-N 0.000 claims 1
- SGRLBYYCMNMZOL-UHFFFAOYSA-N [4-[[5-(1h-indol-2-yl)pyridin-3-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=C1 SGRLBYYCMNMZOL-UHFFFAOYSA-N 0.000 claims 1
- UVGHDHBQPQAISM-UHFFFAOYSA-N [4-[[5-(5-fluoro-1h-indol-2-yl)pyridin-3-yl]amino]phenyl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=C1 UVGHDHBQPQAISM-UHFFFAOYSA-N 0.000 claims 1
- VYTBTGLIMYZDAJ-UHFFFAOYSA-N [4-[[5-(5-fluoro-1h-indol-2-yl)pyridin-3-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(C=C1)=CC=C1C(=O)N1CCNCC1 VYTBTGLIMYZDAJ-UHFFFAOYSA-N 0.000 claims 1
- JHLYSHJWXMJURV-UHFFFAOYSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCCN(C)CC1 JHLYSHJWXMJURV-UHFFFAOYSA-N 0.000 claims 1
- VREHNJGXNKBGFR-UHFFFAOYSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 VREHNJGXNKBGFR-UHFFFAOYSA-N 0.000 claims 1
- ICDZULFHPSAEPS-UHFFFAOYSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCN(C(C)C)CC1 ICDZULFHPSAEPS-UHFFFAOYSA-N 0.000 claims 1
- ZUPXVNHSBSFWJC-QFIPXVFZSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C=C(C(=CC=1)NC=1N=C(C=NC=1)C=1NC2=CC=CC=C2C=1)OC)N1CCCC1 ZUPXVNHSBSFWJC-QFIPXVFZSA-N 0.000 claims 1
- HYNJDSXEWIFBRF-UHFFFAOYSA-N [4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone Chemical compound C1CN(CCOC)CCN1C(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 HYNJDSXEWIFBRF-UHFFFAOYSA-N 0.000 claims 1
- QMKQGTZXNUZQKC-UHFFFAOYSA-N [4-[[6-(4-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(F)=C3C=2)C(OC)=CC=1C(=O)N1CCNCC1 QMKQGTZXNUZQKC-UHFFFAOYSA-N 0.000 claims 1
- IUHWUPCYQXSYOL-UHFFFAOYSA-N [4-[[6-(4-hydroxy-1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC(O)=C3C=2)=N1 IUHWUPCYQXSYOL-UHFFFAOYSA-N 0.000 claims 1
- IGGPEUBUKSEHCZ-UHFFFAOYSA-N [4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-hydroxyphenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(O)=CC=1C(=O)N1CCNCC1 IGGPEUBUKSEHCZ-UHFFFAOYSA-N 0.000 claims 1
- BOCABTCVUZPNCI-UHFFFAOYSA-N [4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 BOCABTCVUZPNCI-UHFFFAOYSA-N 0.000 claims 1
- CMTPWEJEADPAFJ-OAHLLOKOSA-N [4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(3r)-3-methylpiperazin-1-yl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN[C@H](C)C1 CMTPWEJEADPAFJ-OAHLLOKOSA-N 0.000 claims 1
- CMTPWEJEADPAFJ-HNNXBMFYSA-N [4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(3s)-3-methylpiperazin-1-yl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN[C@@H](C)C1 CMTPWEJEADPAFJ-HNNXBMFYSA-N 0.000 claims 1
- BDAFYQPNCMBBGU-UHFFFAOYSA-N [5-[[5-(5-fluoro-1h-indol-2-yl)pyridin-3-yl]amino]pyridin-2-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(C=N1)=CC=C1C(=O)N1CCNCC1 BDAFYQPNCMBBGU-UHFFFAOYSA-N 0.000 claims 1
- SGLFFQKYUVAORF-UHFFFAOYSA-N [5-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]pyridin-2-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1NC(C=N1)=CC=C1C(=O)N1CCNCC1 SGLFFQKYUVAORF-UHFFFAOYSA-N 0.000 claims 1
- LUMYNPZLRZBLQF-UHFFFAOYSA-N [5-chloro-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-2-methoxyphenyl]-piperazin-1-ylmethanone Chemical compound COC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)=C(Cl)C=C1C(=O)N1CCNCC1 LUMYNPZLRZBLQF-UHFFFAOYSA-N 0.000 claims 1
- VNHSDZLHPCFUJV-UHFFFAOYSA-N [6-[[5-(5-fluoro-1h-indol-2-yl)pyridin-3-yl]amino]pyridin-3-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(N=C1)=CC=C1C(=O)N1CCNCC1 VNHSDZLHPCFUJV-UHFFFAOYSA-N 0.000 claims 1
- UONRFQNJFBKWEB-UHFFFAOYSA-N [6-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 UONRFQNJFBKWEB-UHFFFAOYSA-N 0.000 claims 1
- FLHZZIIHBLTSNH-UHFFFAOYSA-N [6-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]-morpholin-4-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)N=CC=1C(=O)N1CCOCC1 FLHZZIIHBLTSNH-UHFFFAOYSA-N 0.000 claims 1
- IRDCGQYTXLOSOM-UHFFFAOYSA-N acetic acid;[4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]phenyl]-morpholin-4-ylmethanone Chemical compound CC(O)=O.C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 IRDCGQYTXLOSOM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- PHEQIDUACUIYEG-UHFFFAOYSA-N n-(1,2-diethylpyrazolidin-4-yl)-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound C1N(CC)N(CC)CC1NC(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 PHEQIDUACUIYEG-UHFFFAOYSA-N 0.000 claims 1
- FQNVEWSIRAAFDY-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-4-[6-(1h-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)NCC(O)CO)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 FQNVEWSIRAAFDY-UHFFFAOYSA-N 0.000 claims 1
- UGOJBVXTCWYKAB-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 UGOJBVXTCWYKAB-UHFFFAOYSA-N 0.000 claims 1
- PSFHIIUZBHXNOR-UHFFFAOYSA-N n-(azetidin-3-yl)-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)NC1CNC1 PSFHIIUZBHXNOR-UHFFFAOYSA-N 0.000 claims 1
- FQNVEWSIRAAFDY-KRWDZBQOSA-N n-[(2s)-2,3-dihydroxypropyl]-4-[6-(1h-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)NC[C@H](O)CO)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 FQNVEWSIRAAFDY-KRWDZBQOSA-N 0.000 claims 1
- ULIMCJSUTRFRIF-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-fluoro-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound C1=C(F)C(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 ULIMCJSUTRFRIF-UHFFFAOYSA-N 0.000 claims 1
- QFDRBXUQNMKNAH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-4-[5-(1h-indol-2-yl)pyridin-3-yl]benzamide Chemical compound C1=CC(C(=O)NCCN(CC)CC)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=C1 QFDRBXUQNMKNAH-UHFFFAOYSA-N 0.000 claims 1
- GLWMBNCIIMAGKE-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 GLWMBNCIIMAGKE-UHFFFAOYSA-N 0.000 claims 1
- TUNJGJAVESBYRU-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 TUNJGJAVESBYRU-UHFFFAOYSA-N 0.000 claims 1
- QEHZTXHMFSBBQW-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 QEHZTXHMFSBBQW-UHFFFAOYSA-N 0.000 claims 1
- JWJMWQRKAQBITG-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[6-(1h-indol-2-yl)pyrazin-2-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCCN(C)C)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 JWJMWQRKAQBITG-UHFFFAOYSA-N 0.000 claims 1
- VTNHHYGXQQBHGX-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[[6-(1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 VTNHHYGXQQBHGX-UHFFFAOYSA-N 0.000 claims 1
- KRAFXUXYGUZYOZ-UHFFFAOYSA-N n-ethyl-n-(2-hydroxyethyl)-4-[6-(1h-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)N(CCO)CC)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 KRAFXUXYGUZYOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 claims 1
- BPRBMHIBHVTUIE-UHFFFAOYSA-N tert-butyl 3-[[4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzoyl]amino]azetidine-1-carboxylate Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)NC1CN(C(=O)OC(C)(C)C)C1 BPRBMHIBHVTUIE-UHFFFAOYSA-N 0.000 claims 1
- IHYDKONBGFJEEL-UHFFFAOYSA-N tert-butyl 3-[[[4-[6-(1h-indol-2-yl)pyrazin-2-yl]benzoyl]amino]methyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1CNC(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=C1 IHYDKONBGFJEEL-UHFFFAOYSA-N 0.000 claims 1
- YDUPFVYOLHJSGF-UHFFFAOYSA-N tert-butyl n-[1-[4-[[6-(5-fluoro-1h-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzoyl]azetidin-3-yl]carbamate Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CC(NC(=O)OC(C)(C)C)C1 YDUPFVYOLHJSGF-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0601379.1 | 2006-06-22 | ||
| SE0601379 | 2006-06-22 | ||
| US85006706P | 2006-10-06 | 2006-10-06 | |
| US60/850,067 | 2006-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009101911A true RU2009101911A (ru) | 2010-07-27 |
Family
ID=38566263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009101911/04A RU2009101911A (ru) | 2006-06-22 | 2007-06-21 | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080039450A1 (enExample) |
| EP (1) | EP2044051B1 (enExample) |
| JP (1) | JP2009541268A (enExample) |
| CN (1) | CN101472912A (enExample) |
| AT (1) | ATE456565T1 (enExample) |
| AU (1) | AU2007263017A1 (enExample) |
| BR (1) | BRPI0713328A2 (enExample) |
| CA (1) | CA2654358A1 (enExample) |
| DE (1) | DE602007004618D1 (enExample) |
| ES (1) | ES2340093T3 (enExample) |
| RU (1) | RU2009101911A (enExample) |
| WO (1) | WO2007147874A1 (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5302883B2 (ja) | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| US20100247517A1 (en) * | 2007-11-22 | 2010-09-30 | Boehringer Ingelheim Internationational GmbH | Use of mnk inhibitors for the treatment of alzheimer's disease |
| EP2265270A1 (en) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| EA014100B1 (ru) * | 2008-02-21 | 2010-08-30 | Общество С Ограниченной Ответственностью "Валексфарм" | Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| KR20110045019A (ko) | 2008-08-26 | 2011-05-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물을 위한 티에노피리미딘 |
| JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| DK2379525T3 (en) | 2008-12-19 | 2015-10-19 | Boehringer Ingelheim Int | Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
| US9260730B2 (en) | 2009-05-07 | 2016-02-16 | Aquatech Bioenergy LLC | Method and system for collecting ethanol from aquatic plants |
| WO2011073154A1 (en) | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists and uses thereof |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| AR080328A1 (es) | 2010-02-26 | 2012-03-28 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros |
| EA201201191A1 (ru) | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| AU2012225805B2 (en) | 2011-03-04 | 2017-03-02 | Lexicon Pharmaceuticals, Inc. | MST1 kinase inhibitors and methods of their use |
| WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| WO2012156367A1 (en) * | 2011-05-17 | 2012-11-22 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| CN103717604B (zh) * | 2011-06-01 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的氨基咪唑并哒嗪 |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なｃｃｒ２拮抗薬 |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| AU2012308570B2 (en) | 2011-09-14 | 2016-11-10 | Samumed, Llc | Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors |
| MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| IN2014CN02501A (enExample) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| SI2814820T1 (sl) * | 2012-02-17 | 2016-10-28 | University Of Cape Town | Sredstva proti malariji |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2917185B1 (en) | 2012-11-09 | 2017-05-10 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| HK1208025A1 (en) | 2012-11-19 | 2016-02-19 | 拜耳医药股份公司 | Aminoimidazopyridazines |
| JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換逆ピリミジンＢｍｉ−１阻害剤 |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| CN105120862A (zh) | 2013-01-08 | 2015-12-02 | 萨穆梅德有限公司 | Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用 |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| KR102232595B1 (ko) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| AU2014359456B2 (en) | 2013-12-04 | 2019-01-24 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| AU2015257917C1 (en) | 2014-05-07 | 2019-03-14 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049565A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| WO2016140501A1 (en) * | 2015-03-04 | 2016-09-09 | Kainos Medicine, Inc. | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| WO2017004537A1 (en) | 2015-07-02 | 2017-01-05 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024003A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
| TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| TW201734003A (zh) | 2016-01-05 | 2017-10-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物 |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| DK3464285T3 (da) | 2016-06-01 | 2022-12-19 | Biosplice Therapeutics Inc | Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid |
| AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3528808B1 (en) | 2016-10-21 | 2021-10-06 | BioSplice Therapeutics, Inc. | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| MX394700B (es) | 2017-02-14 | 2025-03-24 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| AU2018350980C1 (en) | 2017-10-18 | 2024-12-12 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
| US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
| CN112088157B (zh) | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| CN118076354A (zh) * | 2021-08-05 | 2024-05-24 | 4E治疗公司 | 用mnk抑制剂治疗偏头痛的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459266A (en) * | 1994-02-04 | 1995-10-17 | Hoechst Celanese Corporation | Substituted pyrazines |
| US5430123A (en) * | 1994-02-04 | 1995-07-04 | Hoechst Celanese Corporation | Polymer compositions containing substituted pyrazines |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| NZ537155A (en) * | 2002-05-23 | 2006-09-29 | Cytopia Pty Ltd | Protein kinase inhibitors |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| EP1899353A1 (en) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
-
2007
- 2007-06-21 US US11/821,565 patent/US20080039450A1/en not_active Abandoned
- 2007-06-21 AT AT07786791T patent/ATE456565T1/de not_active IP Right Cessation
- 2007-06-21 DE DE602007004618T patent/DE602007004618D1/de active Active
- 2007-06-21 JP JP2009515885A patent/JP2009541268A/ja active Pending
- 2007-06-21 CA CA002654358A patent/CA2654358A1/en not_active Abandoned
- 2007-06-21 EP EP07786791A patent/EP2044051B1/en active Active
- 2007-06-21 BR BRPI0713328-6A patent/BRPI0713328A2/pt not_active IP Right Cessation
- 2007-06-21 WO PCT/EP2007/056213 patent/WO2007147874A1/en not_active Ceased
- 2007-06-21 RU RU2009101911/04A patent/RU2009101911A/ru not_active Application Discontinuation
- 2007-06-21 CN CNA200780022963XA patent/CN101472912A/zh active Pending
- 2007-06-21 AU AU2007263017A patent/AU2007263017A1/en not_active Abandoned
- 2007-06-21 ES ES07786791T patent/ES2340093T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2340093T3 (es) | 2010-05-28 |
| AU2007263017A1 (en) | 2007-12-27 |
| ATE456565T1 (de) | 2010-02-15 |
| CN101472912A (zh) | 2009-07-01 |
| BRPI0713328A2 (pt) | 2012-10-30 |
| CA2654358A1 (en) | 2007-12-27 |
| US20080039450A1 (en) | 2008-02-14 |
| WO2007147874A1 (en) | 2007-12-27 |
| JP2009541268A (ja) | 2009-11-26 |
| DE602007004618D1 (de) | 2010-03-18 |
| EP2044051B1 (en) | 2010-01-27 |
| EP2044051A1 (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541268A5 (enExample) | ||
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| RU2413726C2 (ru) | Замещенные биарильные аналоги пиперазинилпиридина, их применение в терапии, фармацевтическая композиция, фармацевтический препарат, способы уменьшения проводимости кальция и ингибирования связывания капсаициновых рецепторов | |
| JP2023514872A5 (enExample) | ||
| JP2004534010A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2498983C2 (ru) | Соединения фениламинопиримидина и их применения | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| RU2007121505A (ru) | Соединения и композиции как ингибиторы протеинкиназы | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
| JP2014511869A5 (enExample) | ||
| JP2013510876A5 (enExample) | ||
| JP2009526072A5 (enExample) | ||
| JP2017505794A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| ME01507B (me) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| RU2012132426A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ | |
| JP2015524837A5 (enExample) | ||
| JP2009513575A5 (enExample) | ||
| JP2010510319A5 (enExample) | ||
| HRP20160118T1 (hr) | HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs) | |
| RU2009104340A (ru) | Производные [4,5']бипиримидинил-6,4'-диамина в качестве ингибиторов протеинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110602 |